Skip to main content


ESMO 2019: PARP Inhibitor Update

October 25, 2019

At the European Society of Medical Oncology annual congress (September 26-30, 2019; Barcelona, Spain), a variety of important studies were highlighted on PARP inhibitors across a variety of disease types.

Journal of Clinical Pathways was onsite to provide coverage of the most relevant and important sessions of the meeting.

PARP Inhibitors in Front-Line and Maintenance Therapy of Ovarian Cancer: A Changing Standard of Care

Robert L Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the potential integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, as well as the larger PARP inhibitor landscape in this setting. 

Read More


Maintenance Regimen With PARP Inhibitor Shows Survival Benefit in Ovarian Cancer

New data demonstrates the benefit of a more intensive maintenance combination regimen for ovarian cancer regardless of BRCA mutation.

Read More


PARP Inhibitor Provides Superior PFS in Patients With Castration-Resistant Prostate Cancer

A clinically meaningful benefit in radiographic PFS after PARP inhibitor therapy was observed in men with metastatic, castration-resistant prostate cancer who had progressed on prior therapy. 

Read More


Addition of PARP Inhibitor to Front-Line Chemo, Maintenance in High-Grade Ovarian Cancer

The combination of a PARP inhibitor with front-line combination chemotherapy and continued PARP inhibitor maintenance significantly extends PFS in patients with newly diagnosed ovarian serous carcinoma, according to new research. 

Read More

Back to Top